Cannabis info and related links and post from around the web
Classic table games have always been popular, and not only in online casinos. Many players download simple games from app markets to play for free, although the majority prefer to play certain titles for real funds. The most common table and card games are always accessible on gambling sites, as they’re classics. Any best online […]
The post Popular Classic Table Games at Any NZ Casino Online appeared first on Stoner | Pictures | Stoners Clothing | Blog | StonerDays.
Cannabis is now in the middle of a rare federal pivot. President Trump has signed an executive order directing the federal government to move marijuana toward reclassification under federal law. Some see the shift as long overdue recognition of medical reality. Others worry it could deepen federal control over a plant that remains illegal nationwide.
President Trump announced during a press conference today that he has directed marijuana to be removed from the most restrictive category of the Controlled Substances Act and placed into Schedule III, a class reserved for substances deemed to have accepted medical use but subject to regulation.
Gathering in the Oval Office, the President directed Attorney General Pam Bondi to move what federal law still calls “marijuana” from Schedule I to Schedule III, marking the first time since 1970 that cannabis would no longer be listed alongside drugs considered to have no medical value.
“We have people begging for me to do this. People in great pain,” the President said. He was flanked by health officials. “I want to emphasize [that] the order I’m about to sign is not the legalization. It does not legalize marijuana in any shape or form and in no way sanctions its use as a recreational drug.”
“Some people are literally dying with tremendous pain and this can literally stop it in many cases and they have their sense about them.”
“I promised to be the president of common sense and that is exactly what we’re doing.”
“I’ve never been inundated by so many people as I have about this particular reclassification.”
“When you see polls show 82% of people want this.”
Placed in Schedule I during the Nixon administration, cannabis was legally defined as having a high potential for abuse and no accepted medical use. Other Schedule I drugs include heroin, LSD, and ecstasy.
Schedule III drugs, by contrast, are recognized as having medical applications. They include ketamine, anabolic steroids, and products like Tylenol with codeine. Fentanyl, notably, remains a Schedule II drug, despite being linked to 48,422 overdose deaths in 2024 alone. Cannabis has no known lethal overdose threshold.
Public opinion has long diverged from federal policy. Roughly 64% of Americans support full legalization, and more than 90% support medical use. 24 states have legalized adult use, most recently Ohio and Delaware, while 42 states allow medical cannabis, including Mississippi.
The practical effects of rescheduling remain uncertain. Federal arrests for marijuana are rare. Enforcement largely happens at the state level.
The most immediate impact could be financial. Moving cannabis out of Schedule I would remove the tax penalties imposed by IRS code 280E, which currently prevents cannabis businesses from deducting ordinary expenses. The tax artificially inflates their costs of doing business. These higher costs are then passed on to the consumer in the form of higher prices for retail cannabis products.
“This change will also likely benefit cannabis consumers by resulting in lower overall prices for retail products, further incentivizing them to abandon the underground market,” said NORML Executive Director Paul Armentano.
Numerous federal statutes are tied specifically to cannabis’ Schedule I status, touching tax law, housing access, employment protections, gun ownership, and more.
Rescheduling could improve a person’s ability to secure federal housing, maintain employment protections, or access medical cannabis through veterans’ programs. It could also strengthen certain workers’ compensation claims.
But those potential gains come with significant caveats.
Critics warn that placing cannabis in Schedule III may expose THC to greater federal oversight, particularly from agencies like the FDA, without ending prohibition or protecting existing state markets.
Marijuana Policy Project Executive Director Adam Smith said the organization supports descheduling rather than rescheduling, paired with basic consumer safety rules.
“Schedule 3 is a compromise position that was initially from the previous administration that wanted to appear as if they were backing reform without actually addressing the problem,” Smith said. “Certainly, any progress is progress.”
Some in the cannabis industry worry that Schedule III could open the door to pharmaceutical dominance. Federal law, however, still places limits on that scenario.
Research may become easier under Schedule III, but companies would still need FDA approval for specific drugs derived from federally approved cannabis sources. Pharmaceutical companies cannot simply sell plant-based cannabis products through pharmacies.
“That plant material itself is not going to be a pharmaceutical product,” Smith said.
Several cannabis-related drugs already hold FDA approval, including Marinol (synthetic THC), nabilone, and Epidiolex. Despite their existence, the state-legal cannabis market has grown into a $45 billion industry.
The president cannot directly reschedule a drug. But he can order the Attorney General to do so.
Under the Controlled Substances Act, the Attorney General has the authority to reclassify substances. Historically, that power has been delegated to the Drug Enforcement Administration, which rejected five previous rescheduling petitions.
If Attorney General Bondi proceeds, the change would be published in the Federal Register and likely face legal challenges.
Anti-cannabis group Project SAM has already urged opposition. In an August 28 letter to Bondi, nine members of Congress argued that rescheduling would “send a message to kids that marijuana is not harmful.”
“I think this will be tied up in litigation for quite some time,” Armentano said.
The Executive Order is likely to energize Trump’s supporters who favor cannabis reform. Politically, the move is largely symbolic. It reflects a reality that the public reached long ago.
“It’s a recognition from the federal government that marijuana has medical value,” Armentano said. “Claims that cannabis poses unique harms to health, or that it’s not useful for treating chronic pain and other ailments, have now been rejected by the very federal agencies that formerly perpetuated them.”
That acknowledgment follows decades of advocacy and research, including testimony from cancer patients, epilepsy patients, and others who have relied on cannabis therapeutically.
Rescheduling could also influence state policy debates. Lawmakers opposing reform will no longer be able to cite Schedule I as justification.
NORML Political Director Morgan Fox said Republican backing could shift the landscape.
“Having a Republican administration backing this effort will likely embolden more Republican lawmakers, many of whom have privately endorsed marijuana policy reform, to now do so publicly,” Fox said.
Placing cannabis in Schedule I was one of the foundational acts of the modern drug war. The designation carried cascading consequences.
Parents who used marijuana were treated like heroin users by child welfare systems. Banks servicing cannabis businesses were viewed as criminal enterprises. Millions lost access to housing, education, employment, or financial services.
For some, the consequences were fatal. Prohibition fueled violence, robberies, and long-term criminal records that continue to shape lives.
Activists have long argued the designation was political, not scientific. Former Nixon administration officials later acknowledged it was designed to suppress youth and minority voters during the Vietnam War and Civil Rights era.
In 2022, President Biden ordered a review of cannabis’ Schedule I status. The Department of Health and Human Services concluded that modern science supported rescheduling. The process ultimately stalled at the DEA.
The Trump administration has taken a different approach, relying on executive authority rather than prolonged review. The move reflects an expansive view of presidential power and a shift away from DOJ independence.
Trump publicly endorsed Florida’s legalization initiative during last year’s campaign and accepted donations from cannabis companies, including Curaleaf and Trulieve. He has previously floated rescheduling as a trial balloon.
Today’s rescheduling order may carry legal and symbolic weight, but hemp legalization has already reshaped the marketplace.
THC-A flower ships nationwide. Delta-8 drinks line shelves in prohibition states. In that context, rescheduling arrives late, after federal hemp policy quietly opened the floodgates.
For longtime advocates, however, even partial movement matters.
“No matter what happens, the battle for nationwide cannabis law reform is far from over,” Armentano said.
High Times note: Rescheduling acknowledges medical reality. It does not end prohibition. The fight for decriminalization and full legalization continues.
Shealeah Craighead, Public domain, via Wikimedia Commons
<p>The post Trump Reschedules Marijuana. But, Wait… There’s A Catch first appeared on High Times.</p>
The safety of THC vaping products is a critical concern for consumers and regulators alike, given the unique challenges associated with inhaled substances. Ensuring product integrity from manufacturing to consumption involves adherence to specific standards…
The post SAFETY STANDARDS FOR THC VAPING PRODUCTS appeared first on Greencamp.
CBD products are great for relieving stress and body pains. They can also improve sleep quality. Little wonder they have become popular. With many CBD products on the market, identifying effective and safe products has become a challenge. You won’t go wrong with the famous brand “Popeye club” However, considering the following factors will help you identify […]
The post What You Should Consider When Sourcing Quality CBD Products appeared first on Stoner | Pictures | Stoners Clothing | Blog | StonerDays.
When President Donald Trump announced that he would sign an executive order moving marijuana from Schedule I to Schedule III, he didn’t frame it as a cultural breakthrough or a political victory.
He framed it as medicine.
There were no weed jokes, no talk of freedom, no nods to cannabis culture. Instead, Trump spoke about pain, illness, seniors, veterans, and people facing the end of their lives.
And near the end of the event, he made something else unmistakably clear.
“I don’t want it. I’m not taking it,” the president said.
That line captured the deeper story behind the announcement. Trump didn’t just reclassify marijuana. He went out of his way to distance himself from it — personally, culturally, and politically — while still arguing that the federal government could no longer ignore its medical value.
From the outset, the press conference was staged to reinforce that message. Trump was flanked not by advocates or industry figures, but by doctors, researchers, and federal health officials. The language was clinical and emotional, not celebratory.
“We have people begging for me to do this. People in great pain,” Trump said. “Some people are literally dying with tremendous pain, and this can, in many cases, literally stop it.”
He repeatedly emphasized what the executive order was not.
“It does not legalize marijuana in any shape or form and in no way sanctions its use as a recreational drug,” he said, likening cannabis to prescription painkillers — substances that can be medically useful, but destructive when abused.
Trump framed rescheduling not as an embrace of marijuana, but as an acknowledgment of reality. In his telling, this wasn’t about liking cannabis. It was about responding to suffering.
“When you see polls show 82% of people want this,” he said, adding that he received “no calls on the other side of it.”
That populist framing mattered. Trump presented the decision as something driven not by ideology, but by pressure from patients, families, and doctors — especially older Americans and veterans.
He returned repeatedly to the idea of dignity at the end of life, contrasting cannabis with opioid painkillers that leave patients sedated and disconnected.
“They have their senses about them,” he said. “Painkillers don’t allow that. Don’t allow them to die with dignity, frankly.”
The officials who followed him reinforced the same themes. Rescheduling, they argued, would make research easier and more rigorous. It would allow scientists to study dosing, safety, benefits, and risks without the barriers imposed by Schedule I status. It would replace anecdote with data.
What was notably absent from the framing were themes long central to cannabis reform: criminal justice, racial equity, or the normalization of adult use. Trump didn’t mention dispensaries, legalization campaigns, or state markets. The word “weed” never entered the room.
Instead, marijuana was positioned alongside other tightly regulated medical tools — something to be studied, prescribed carefully, and controlled.
That choice may frustrate advocates seeking broader reform. But it also helps explain why this move happened now, under this administration, when previous presidents declined to act.
By separating cannabis from identity and lifestyle, Trump neutralized arguments that have stalled reform for decades. He didn’t ask Americans to like marijuana. He asked them to recognize pain.
“I promised to be the president of common sense,” he said. “And that is exactly what we’re doing.”
Whether the rescheduling survives legal challenges or reshapes federal policy remains to be seen. But the message Trump delivered was already clear.
He didn’t sell marijuana reform as liberation.
He sold it as medicine — and made sure everyone knew he wanted no part of it himself.
Photo: Shutterstock
<p>The post Trump Reclassified Marijuana — Then Told America He Doesn’t Want It first appeared on High Times.</p>
Frozen Russian assets are at the heart of the EU summit currently in Brussels where the EU is deciding whether it can use the funds to help Ukraine. It looks likely.
Source link
In a crowded cannabis landscape, few brands manage to balance quality, culture, and consistency as seamlessly as Singing Kush. Rooted in craftsmanship and elevated by intentional branding, Singing Kush isn’t just about consumption—it’s about experience. Every detail, from flower selection to presentation, reflects a deep respect for cannabis as both an art form and a
